Literature DB >> 25262508

Study on novel galantaminehydrobromide sustained-release capsules and itsin vitro releasing property.

Kun Li1, Shuoye Yang2.   

Abstract

In present study, we prepared a novel galantamine hydro bromide sustained-release capsules with the new manufacturing technology, extrusion-spheronization method, and the optimized preparative formulation. A simple, rapid and accurate high performance liquid chromatography method (HPLC) was developed and validated for the quantification and release evaluation of galantamine hydro bromide. Experimental results showed that the method was specific, sensitive and reliable, could be effectively applied to the in vitro release study of galantamine hydro bromide sustained-release capsules. Our resulting samples had superior properties, worked better as sustained-release carriers and lasted longer hours to release drugs compared with the marketed control, Razadyne ER. The in vitro releasing characteristics of different batches of preparations are quite similar with each other, the total release proportions of galantamine hydro bromide from sustained-release capsules reached higher than 90 % within 12 h. The testing sustained-release preparation may be a promising new product for curing the related diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25262508

Source DB:  PubMed          Journal:  Pak J Pharm Sci        ISSN: 1011-601X            Impact factor:   0.684


  2 in total

1.  LC-MS bioanalysis of targeted nasal galantamine bound chitosan nanoparticles in rats' brain homogenate and plasma.

Authors:  Mahmoud Agami; Rasha A Shaalan; Saied F Belal; Marwa A A Ragab
Journal:  Anal Bioanal Chem       Date:  2021-06-25       Impact factor: 4.142

2.  Release property study on the novel divalproex sodium enteric-coated capsules.

Authors:  Shuoye Yang; Xin Wang; Jiangsong Jia; Pengyuan Li
Journal:  Saudi Pharm J       Date:  2016-04-26       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.